🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Themis Medicare Limited THEMISMED NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.themismedicare.com
Company Profile ↓
₹118.61
-3.80% 1Y
Mkt Cap₹1,092.40 Cr
P/E36.61
P/B2.70
Div. Yield0.43%
52W High₹142.46
52W Low₹66.07
Book Value₹43.28
EPS (TTM)₹3.24

Company Overview

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is based in Mumbai, India.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 36.6, below the sector median of 40.0.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.25.

Recent Developments

  • Mar 2026 Revenue of ₹342.24 Cr (-15.6% YoY); net profit ₹1.14 Cr.
  • Trailing 12 Months Year-on-year growth — revenue -15.6%, earnings -96.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR -0.2%, profit CAGR -72.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-0.22%
1 Year:-15.60%

Compounded Profit Growth

5 Years:-72.81%
1 Year:-96.17%

Stock Price Performance

1 Year:-3.80%
6 Months:+20.28%
3 Months:+39.61%
1 Month:+15.26%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 69% of range
₹66.07 ₹142.46
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.54 · Neutral
Price Performance
1M+15.26%
3M+39.61%
6M+20.28%
1Y-3.80%
Valuation vs Sector

P/E of 36.61 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -0.2% CAGR over 5 years.
  • Earnings shrank at -72.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
36.61
Industry PE
39.97
Forward P/E est.
73.22
PEG Ratio
-
Book Value
₹43.28
Price to Book
2.70
P/S
3.15
EV/EBITDA
2,965.86
Dividend Yield
0.43%

Growth (CAGR)

Revenue 5Y
-0.22%
Profit 5Y
-72.81%
Revenue (YoY)
-15.60%
Earnings (YoY)
-96.17%

Profitability & Returns

ROCE
2.92%
ROE
0.29%
ROA
0.19%
Profit Margin
0.33%
Op Margin
-2.90%
Gross Margin
62.17%
EPS (Latest Qtr)
₹0.96
EPS (TTM)
₹3.24

Balance Sheet & Liquidity

Debt/Equity
0.25
Quick Ratio
1.35
Current Ratio
1.84
Debt
₹100.09 Cr
Total Assets
₹597.91 Cr
Current Assets
₹304.98 Cr
Working Capital
₹138.82 Cr

Ownership

Promoter Holding
74.89%
Chg in Prom Hold
-1.07%
FII / Inst Holding
0.03%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹1,092.40 Cr
Total Revenue (TTM)
₹342.24 Cr
EBITDA
₹22.94 Cr
Free Cash Flow
₹-8.14 Cr
Operating Cash Flow
₹-3.27 Cr
Shares Outstanding
₹9.21 Cr
Gross Margin
62.17%
Payout Ratio
416.67%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 THEMISMED Themis Medicare Limited NSEPHARMA 118.61 36.61 ₹1,092.40 Cr 0.43% 2.92% 0.29% -0.22% -72.81%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 80.10 Cr96.65 Cr104.78 Cr82.51 Cr97.82 Cr122.99 Cr117.01 Cr93.81 Cr71.70 Cr97.58 Cr77.99 Cr90.13 Cr76.53 Cr
Cost of Revenue --------20.59 Cr52.40 Cr24.15 Cr29.18 Cr23.75 Cr
Gross Profit --------51.11 Cr45.18 Cr53.85 Cr60.96 Cr52.78 Cr
Operating Expenses 69.62 Cr74.91 Cr92.37 Cr74.46 Cr88.53 Cr93.81 Cr99.88 Cr87.84 Cr59.43 Cr57.81 Cr59.51 Cr53.75 Cr51.62 Cr
Operating Income 7.68 Cr18.71 Cr9.34 Cr4.95 Cr6.23 Cr26.77 Cr14.68 Cr3.43 Cr-8.32 Cr-12.63 Cr-5.66 Cr7.21 Cr1.16 Cr
EBITDA 10.48 Cr21.74 Cr12.41 Cr8.05 Cr9.29 Cr29.18 Cr17.13 Cr5.97 Cr-6.14 Cr-9.04 Cr1.89 Cr15.73 Cr14.36 Cr
Interest Expense 2.71 Cr2.49 Cr2.04 Cr2.68 Cr2.16 Cr2.36 Cr2.44 Cr2.79 Cr2.45 Cr2.47 Cr2.76 Cr2.75 Cr2.70 Cr
Pretax Income 10.29 Cr22.51 Cr13.96 Cr8.21 Cr8.74 Cr31.34 Cr17.80 Cr1.66 Cr-11.13 Cr-14.06 Cr-3.45 Cr10.39 Cr9.06 Cr
Tax Provision 1.89 Cr4.32 Cr2.64 Cr84.97 L2.11 Cr6.66 Cr3.50 Cr1.14 Cr-1.46 Cr15.52 L16.49 L29.42 L17.02 L
Net Income 8.41 Cr18.19 Cr11.32 Cr7.37 Cr6.64 Cr24.68 Cr14.29 Cr52.00 L-9.66 Cr-14.22 Cr-3.62 Cr10.09 Cr8.89 Cr
Diluted EPS 0.911.981.230.800.722.681.550.06-1.05-1.54-0.391.090.96

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 202.00 Cr232.00 Cr217.00 Cr210.00 Cr184.00 Cr202.00 Cr231.00 Cr-344.45 Cr376.63 Cr405.51 Cr342.24 Cr
Cost of Revenue --------121.00 Cr139.76 Cr131.99 Cr129.47 Cr
Gross Profit --------223.46 Cr236.87 Cr273.52 Cr212.76 Cr
Operating Expenses 184.00 Cr194.00 Cr184.00 Cr184.00 Cr181.00 Cr166.00 Cr181.00 Cr-166.50 Cr197.61 Cr234.40 Cr222.69 Cr
Operating Income 7.00 Cr26.00 Cr26.00 Cr18.00 Cr-6.00 Cr28.00 Cr40.00 Cr-56.96 Cr39.26 Cr39.12 Cr-9.93 Cr
EBITDA 18.00 Cr38.00 Cr33.00 Cr25.00 Cr2.00 Cr36.00 Cr49.00 Cr-91.00 Cr73.32 Cr59.64 Cr22.94 Cr
Interest Expense 15.00 Cr12.00 Cr12.00 Cr12.00 Cr12.00 Cr13.00 Cr13.00 Cr-7.99 Cr7.63 Cr10.04 Cr10.69 Cr
Pretax Income 5.00 Cr17.00 Cr18.00 Cr11.00 Cr-13.00 Cr27.00 Cr41.00 Cr-72.51 Cr53.44 Cr39.67 Cr1.93 Cr
Tax Provision -1.00 Cr1.87 Cr1.62 Cr11.00 L1.95 Cr2.16 Cr5.74 Cr-15.61 Cr9.92 Cr9.84 Cr78.45 L
Net Income 6.00 Cr16.00 Cr16.00 Cr11.00 Cr-11.00 Cr25.00 Cr36.00 Cr-56.90 Cr43.52 Cr29.83 Cr1.14 Cr
Diluted EPS 0.731.911.771.23-1.172.703.887.916.174.723.24-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 277.00 Cr275.00 Cr289.00 Cr305.00 Cr314.00 Cr350.00 Cr371.00 Cr-513.96 Cr566.42 Cr588.03 Cr597.91 Cr
Current Assets --------264.53 Cr293.17 Cr303.87 Cr304.98 Cr
Cash & Equivalents --------12.55 Cr9.92 Cr6.56 Cr4.54 Cr
Inventory --------68.95 Cr70.57 Cr84.31 Cr81.09 Cr
Receivables --------145.02 Cr177.95 Cr177.10 Cr178.12 Cr
Total Liabilities --------174.51 Cr188.75 Cr185.43 Cr199.33 Cr
Current Liabilities --------139.13 Cr152.98 Cr156.12 Cr166.16 Cr
Long Term Debt --------26.70 Cr25.13 Cr16.88 Cr21.86 Cr
Total Debt 140.00 Cr128.00 Cr82.00 Cr80.00 Cr82.00 Cr100.00 Cr87.00 Cr-92.38 Cr95.79 Cr82.99 Cr100.09 Cr
Total Equity 59.00 Cr75.00 Cr152.00 Cr169.00 Cr158.00 Cr183.00 Cr218.00 Cr-339.44 Cr377.67 Cr402.60 Cr398.58 Cr
Shares Outstanding --------9.20 Cr9.20 Cr9.20 Cr9.21 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 19.00 Cr26.00 Cr-2.00 Cr8.00 Cr11.00 Cr057.00 Cr-16.09 Cr22.09 Cr34.71 Cr-3.27 Cr
Investing Cash Flow -6.00 Cr-7.00 Cr-4.00 Cr-0-4.00 Cr-5.00 Cr-16.00 Cr--23.96 Cr-15.95 Cr-12.17 Cr-2.54 Cr
Financing Cash Flow -18.00 Cr-13.00 Cr5.00 Cr-9.00 Cr-10.00 Cr7.00 Cr-26.00 Cr-13.62 L-8.77 Cr-25.90 Cr3.79 Cr
Capital Expenditure -6.00 Cr-8.00 Cr-5.00 Cr-3.00 Cr-6.00 Cr-5.00 Cr-18.00 Cr--28.75 Cr-18.42 Cr-15.43 Cr-4.87 Cr
Free Cash Flow 13.00 Cr18.00 Cr-7.00 Cr5.00 Cr5.00 Cr-5.00 Cr39.00 Cr--12.66 Cr3.68 Cr19.28 Cr-8.14 Cr
Net Change in Cash -5.00 Cr5.00 Cr-0-1.00 Cr-3.00 Cr2.00 Cr16.00 Cr--7.73 Cr-2.62 Cr-3.36 Cr-2.02 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------64.9%62.9%67.5%62.2%
Operating Margin % 3.5%11.2%12.0%8.6%-3.3%13.9%17.3%-16.5%10.4%9.6%-2.9%
Net Margin % 3.0%6.9%7.4%5.2%-6.0%12.4%15.6%-16.5%11.6%7.4%0.3%
ROE % 10.2%21.3%10.5%6.5%-7.0%13.7%16.5%-16.8%11.5%7.4%0.3%
ROCE % --------15.2%9.5%9.1%-2.3%

Shareholding Pattern

Insiders
74.89%
Institutions
0.03%
Public Float
0.13%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for THEMISMED

Google News hu, 15 Jan 2026

Even though Themis Medicare (NSE:THEMISMED) has lost ₹998m market cap in last 7 days, shareholders are still up 189% over 5 years - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOUVIwUkUxRjJqOFJMRXNGOFdzVVpoeWhwcGtyT25PZW0wRTdOUXA4ZldNei1naWRHUEo3dDFJWTVSbHo2SGRyX2FvOGdvNGhIYVU5S2M1djZOUUgxRUdmdEtEU29TU2Y5TnpWUFhUdXgxOExEbm1qVVlleVVfd0YzbV9ZVG4xVlVDM05xQm…

Google News ue, 16 Sep 2025

Subdued Growth No Barrier To Themis Medicare Limited (NSE:THEMISMED) With Shares Advancing 30% - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPZDQzUktjWXVuQS11MVdxQjU0cDdOZGZseW1falJVMXhGVG5mdkhUYUItT1NHRTdXRDlaY25WdTVQNFJoUGJxR3JxQldJd1U3MHotSnFMWWJnc0ZxT3QwOW1sWmdiTXhTR1d6OUQ4dlZjclN0YzBhMVJjS2M2VVdnNHBtOUJDUkx2bkdsS1…

Google News Fri, 21 Jul 2017

THEMISMED Stock Price and Chart — NSE:THEMISMED - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wc21IcFZzdXZ4TFllX2Jhb3FkMHJMM3VzY1NZVktPZUhiTGM3OGpjNkhhR0ZjdFIyQ3p0MFhqLUFXY2ZzV01LVm8xNnNyaHBHaTAya2duY2xVV3BIZDJ3?oc=5" target="_blank">THEMISMED Stock Price and Chart — NSE:T…

Google News Sat, 02 Aug 2025

Does The Market Have A Low Tolerance For Themis Medicare Limited's (NSE:THEMISMED) Mixed Fundamentals? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPRTlXa190dlM0WnUtcjJ6dnNENzBpa3h6SkxXVDlPZ1hPc3FENWJxeF9naHZxZXVMTmdMclczQUhtNTJMRm5TWjJsN05VSmZJaHFKLWxiemF0TGNfZG1ZTVBFYUxFTWQ0eDVZeWNzMmVrWU43T3VjRWh1UTR5LUt1ZzNUb0VLUDh4dGJYaV…

THEMISMED — Frequently Asked Questions

What is the current share price of Themis Medicare Limited (THEMISMED)?

As of 2026-07-15 09:52 IST, Themis Medicare Limited (THEMISMED) trades at ₹118.61 on NSE. Its 52-week range is ₹66.07 to ₹142.46.

What is the market capitalisation of THEMISMED?

Themis Medicare Limited (THEMISMED) has a market capitalisation of ₹1,092.40 Cr on NSE.

What is the P/E ratio of THEMISMED?

THEMISMED trades at a trailing price-to-earnings (P/E) ratio of 36.61. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.70.

Does THEMISMED pay a dividend?

Themis Medicare Limited (THEMISMED) currently offers a dividend yield of 0.43%.

What is the return on equity (ROE) of THEMISMED?

THEMISMED has a return on equity (ROE) of 0.29%. Its return on capital employed (ROCE) is 2.92%.

Is THEMISMED a good stock to buy?

This page provides a data-driven analysis of Themis Medicare Limited (THEMISMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space